Multiple Myeloma: The First Signs, the Key Blood Test, and Whether It Is Hereditary

A retired teacher blames the ache in her lower back on the garden. She rests, stretches, buys a firmer mattress. Three months later she is still tired by lunchtime, and a routine blood panel ordered for something else comes back with a note nobody expected: total protein high, hemoglobin low, kidney numbers drifting.

That sequence, ordinary symptoms shrugged off and then an odd lab result, is how a large share of multiple myeloma stories begin. This is a cancer of plasma cells, the bone marrow’s antibody factories, and it rarely announces itself with a lump or a dramatic event. Its early clues are the sort of things people attribute to age, stress, or a long winter.

What follows is an honest map of those clues: which symptoms matter, which single blood test carries the most weight, what the results actually mean, and what the evidence says about whether this disease runs in families.

What is the first sign of multiple myeloma?

Ask hematologists what brought their myeloma patients through the door and one answer dominates: bone pain. Mayo Clinic lists it first among symptoms, typically in the spine or chest, and the NHS describes a persistent, dull ache, most often in the back, ribs, or hips, that can worsen with movement. Unlike a pulled muscle, it does not settle over a couple of weeks and can wake people at night.

Fatigue is the runner-up. Plasma cells that multiply out of control crowd the marrow and squeeze out red cell production, so anemia builds slowly. People notice breathlessness on stairs, a heart that races on modest effort, or an afternoon slump that no amount of sleep repairs.

Then there is the third, quieter path. Mayo Clinic notes that myeloma is sometimes discovered by accident during blood work for an unrelated reason. A high total protein, a low hemoglobin, a raised calcium, or a creatinine level that has crept up since the last check prompts a clinician to look further. In these cases the “first sign” is a number on a lab report, not a symptom at all.

The practical lesson: there is no single unmistakable opening signal. What sets myeloma apart is the pattern, back pain that behaves badly, tiredness that is out of proportion, and blood results that do not fit a simple explanation. Any one of these alone is common and usually benign. Two or three together, especially past age 60, is a reason to look closer.

Where does myeloma usually start?

Myeloma begins in the bone marrow, the soft tissue inside bones where blood cells are made. The culprit is the plasma cell, a mature white blood cell whose job is to pump out antibodies against infection. In myeloma, a single plasma cell acquires genetic damage, starts copying itself, and every copy produces the same abnormal antibody, called a monoclonal protein or M protein.

Because marrow runs through the skeleton, the disease is not confined to one spot. MedlinePlus describes it as affecting multiple bones, which is exactly what the word “multiple” refers to. The bones richest in active marrow in adults are the spine, pelvis, ribs, skull, and the long bones of the upper arms and thighs, and those are where pain and weak spots most often appear.

The abnormal plasma cells also send chemical signals that switch on osteoclasts, the cells that dissolve bone, while suppressing the cells that rebuild it. The result is punched-out areas visible on imaging, generalized thinning, and vertebrae that can compress under normal body weight. Mayo Clinic groups these bone problems, along with kidney damage, anemia, and infections, as the main complications of the disease.

Occasionally the clone forms a discrete mass of plasma cells, called a plasmacytoma, in bone or soft tissue. Some people are diagnosed with a single plasmacytoma before any marrow-wide disease is found, and clinicians watch them closely because a portion later develop full myeloma. That is why an unexplained bony mass or a fracture from a minor knock is treated as a signal worth chasing rather than an isolated event.

What are the early warning signs of myeloma?

Clinicians remember the classic features with the acronym CRAB: Calcium, Renal, Anemia, Bone. Each letter is a mechanism, and understanding the mechanism makes the symptom list far less random.

High calcium comes from bone being broken down faster than it is rebuilt. Calcium leaks into the blood and produces thirst, frequent urination, constipation, nausea, and a foggy, drowsy feeling. The NHS notes that severe hypercalcemia can also cause confusion.

Kidney trouble arises because the abnormal antibody fragments, known as light chains, are filtered through the kidneys and can clog the tubules. People rarely feel this early; it shows up as a rising creatinine on a blood test, sometimes with swollen ankles or foamy urine later.

Anemia produces the fatigue, pallor, and breathlessness already described. Bone disease produces pain, height loss from collapsed vertebrae, and fractures from trivial falls.

Beyond CRAB, two further patterns matter:

• Repeated infections, particularly chest and urinary infections, because the marrow produces plenty of the useless M protein and too little of the normal antibodies that fight bacteria.
• Unexplained bruising or nosebleeds, when platelets are crowded out or the thick, protein-laden blood interferes with clotting.

None of these is specific. Constipation, tiredness, back pain, and a chest infection in the same year describes half the adult population. The signal is persistence and clustering, and the tie-breaker is almost always a blood test, which is where the next sections turn.

How long can you go without knowing you have multiple myeloma?

Longer than most people would guess, and the honest answer is that nobody can give a fixed number. Mayo Clinic states that multiple myeloma almost always starts as a benign-looking condition called monoclonal gammopathy of undetermined significance, or MGUS, in which a small clone of plasma cells makes M protein without causing harm. That phase can last for years and produces no symptoms at all.

Between MGUS and active myeloma sits a middle stage, smoldering myeloma. Here the clone is larger and the protein level higher, but there is still no bone damage, anemia, kidney injury, or high calcium. People in this stage feel entirely well. They are usually found only because a blood test was ordered for another reason, and they are monitored rather than treated.

Active disease, when symptoms finally appear, is frequently mistaken for something ordinary. Back pain is attributed to disc trouble. Fatigue is blamed on poor sleep or low mood. A chest infection is just a bad winter. Months can pass between the first ache and the first blood test, and more time between an abnormal protein result and a specialist appointment.

Two things soften this picture. First, MGUS itself is not cancer, and most people who have it never develop myeloma; that evidence is laid out in the next section. Second, the period of silent disease is not wasted time in the sense of missed cure, because myeloma is managed as a long-term condition rather than removed in one operation. The real cost of delay is complications that were preventable: a vertebral fracture, a kidney that has lost function, a severe infection. Those are the reasons to take persistent, unexplained symptoms to a clinician rather than waiting them out.

What is MGUS, and does everyone with it get myeloma?

MGUS is the finding that launches many anxious internet searches. It means a laboratory has detected a monoclonal protein in the blood, but the amount is small, the marrow contains few abnormal plasma cells, and there is no organ damage. Mayo Clinic describes it as a condition that causes no problems in most people.

The numbers are reassuring. According to Mayo Clinic, roughly 1% of people with MGUS progress to multiple myeloma or a related disorder each year. Put another way, a person who lives 20 years with MGUS has a better than three-in-four chance of never developing myeloma from it. The risk does not disappear, which is why follow-up is recommended, but it is far from a countdown.

MGUS becomes more common with age and is often found incidentally, in a protein panel ordered for kidney assessment or a nerve problem. Because it causes no symptoms, most people who have it are never aware of it.

Follow-up is straightforward: periodic blood tests to check that the M protein level is stable, hemoglobin is holding, calcium and kidney function are normal, and free light chains have not shifted. The interval between checks is set by the clinician based on the type and level of protein found.

What MGUS does offer is a window. People carrying the label already have a baseline, so any change is caught early, before bones or kidneys are harmed. That is a genuine advantage over the person whose first myeloma sign is a collapsed vertebra. For someone told they have MGUS, the evidence-based stance is vigilance without dread.

What is the key blood test for multiple myeloma?

If one test defines the search for myeloma, it is serum protein electrophoresis, usually paired with immunofixation. MedlinePlus explains that electrophoresis separates blood proteins by passing an electric current through a sample; each type of protein migrates a characteristic distance and forms a band. In healthy blood, the antibody region shows a broad, smooth curve because thousands of different plasma cell families each contribute a little. In myeloma, one clone dominates, and it produces a sharp, narrow spike, the M spike.

Immunofixation is the follow-up that names the spike. It identifies which class of antibody the clone is making, most often IgG or IgA, and which light chain, kappa or lambda, it carries. That fingerprint becomes the marker the care team follows for years, watching it fall with treatment and rise if the disease stirs.

A companion test, the serum free light chain assay, measures the small antibody fragments that circulate on their own. It catches a subset of myeloma that makes light chains only and would be missed on electrophoresis alone, and it is sensitive enough to detect small shifts early.

A few points people find useful when reading results:

• A monoclonal protein does not by itself mean cancer. MGUS produces one too, at lower levels.
• The size of the spike matters less than the company it keeps: anemia, calcium, kidney function, and marrow findings decide the diagnosis.
• Normal electrophoresis does not fully exclude myeloma if the free light chain assay was not done.

Clinicians typically order these tests when the pattern described earlier appears, or when a routine panel shows unexplained high total protein or low albumin with a high globulin fraction.

What do the other blood and urine tests show?

No single result diagnoses myeloma. The protein tests identify the clone; a cluster of routine tests reveals whether it is doing damage. The NHS describes the diagnostic work-up as a combination of blood tests, urine tests, imaging, and a bone marrow sample.

Test	What it measures	Why it matters in myeloma
Complete blood count	Red cells, white cells, platelets	Low hemoglobin reflects marrow crowding; low platelets can explain bruising
Calcium	Calcium released from bone into blood	Raised levels signal active bone breakdown and cause thirst, constipation, confusion
Creatinine and eGFR	Kidney filtering ability	Light chains can injure kidney tubules; early damage is silent
Albumin and beta-2 microglobulin	Nutrition and cell-turnover proteins	Used together to stage the disease
Urine protein electrophoresis	Light chains spilling into urine	Detects the so-called Bence Jones protein and gauges kidney exposure

Reading these together tells a story. A modest M spike with normal calcium, kidneys, hemoglobin, and marrow points to MGUS or smoldering disease. The same spike alongside anemia and a creeping creatinine points to active myeloma that needs treatment.

Two practical notes. Urine is often collected over 24 hours rather than as a single sample, because light chain excretion varies through the day. Kidney results also deserve interpretation in context, since dehydration and some common medicines can nudge creatinine upward, so clinicians repeat or adjust before drawing conclusions.

Staging systems used in myeloma combine albumin, beta-2 microglobulin, and genetic features of the plasma cells. They help the team choose a treatment approach and communicate risk; they are not a verdict, and how any individual will respond cannot be read from a lab sheet.

How is multiple myeloma confirmed?

Blood tests raise the suspicion; marrow and imaging settle it. A bone marrow biopsy, usually taken from the back of the pelvis under local anesthetic, is the decisive step. A pathologist counts the plasma cells and checks whether they are a single clone. Under the international consensus criteria described in the NIH National Cancer Institute’s patient summary, active myeloma is diagnosed when clonal plasma cells make up at least 10% of the marrow, or a plasmacytoma is proven on biopsy, together with evidence of organ damage or specific laboratory markers that predict imminent damage.

The marrow sample also goes for genetic testing. Certain chromosome changes in the plasma cells are associated with faster-moving disease, and the results feed into the staging described earlier. This is not a hereditary genetic test; it examines the cancer cells, not the person’s inherited DNA, a distinction that causes understandable confusion and is addressed in the section on heredity.

Imaging maps the bones. The NHS lists X-rays, CT, MRI, and PET scans among the options. Older skeletal surveys with plain X-rays have largely given way to whole-body low-dose CT, which picks up small punched-out lesions more reliably, and MRI, which shows marrow involvement before bone has visibly thinned. PET-CT highlights metabolically active disease and is useful when soft-tissue plasmacytomas are suspected.

People often ask why so many tests are needed when the blood already shows an M spike. The answer is that the treatment decision hinges on the difference between MGUS, smoldering myeloma, and active disease, and only the marrow count and organ assessment can make that call. Skipping steps risks either treating someone who needed only monitoring or watching someone who needed treatment now.

What can be mistaken for multiple myeloma?

Confusion runs in both directions. Myeloma is often initially mislabeled as something ordinary, and other conditions can mimic its laboratory picture.

On the first side, the usual suspects are mechanical back pain, osteoporosis, and osteoarthritis. An older adult with a vertebral compression fracture is frequently assumed to have osteoporosis alone; it takes a clinician who notices the accompanying anemia or raised protein to order the electrophoresis. Anemia is routinely attributed to iron deficiency or aging. Recurrent infections are put down to a hard winter. Kidney impairment is filed under diabetes or blood pressure. Each of these explanations is usually correct, which is exactly why myeloma slips past.

On the second side, a monoclonal protein can appear in several conditions that are not myeloma:

• MGUS, by far the most common, which requires monitoring but not treatment.
• Waldenström macroglobulinemia, a lymphoma-like disorder producing IgM protein, which behaves differently and is treated differently.
• Light chain amyloidosis, in which the light chains fold abnormally and deposit in the heart, kidneys, or nerves.
• Some chronic infections and autoimmune diseases, which occasionally produce a small, transient spike.

Bone lesions on imaging have their own list of look-alikes, including metastases from breast, prostate, lung, or kidney cancer, and lymphoma in bone. The pattern of lesions, the protein studies, and the marrow findings separate them.

The takeaway for readers is not to self-diagnose from a lab printout but to notice when explanations are being stacked. Back pain plus anemia plus a kidney blip, each individually explained away, is the classic scenario where someone eventually asks whether one condition accounts for all three. Mayo Clinic’s advice to seek evaluation for persistent, unexplained symptoms exists for precisely this pattern.

Is multiple myeloma hereditary?

Mostly no, with an important footnote. Myeloma is not passed down the way a single-gene condition such as cystic fibrosis is. There is no routine genetic test that predicts who will develop it, and the vast majority of people diagnosed have no affected relative.

The footnote is that family history does shift the odds. Mayo Clinic lists having a sibling or parent with multiple myeloma among the risk factors, and the NHS notes the disease is slightly more common in people with a close relative who has had it. The effect is real but modest, and it is thought to reflect a mix of shared inherited variations that each nudge risk a little, rather than one faulty gene. Studies of families with several affected members suggest that whatever predisposition exists often shows up first as MGUS in relatives.

Here the distinction raised earlier becomes essential. When a person with myeloma is told their cancer has a “genetic abnormality” such as a chromosome translocation, that refers to mutations inside the malignant plasma cells, acquired during life. These changes are not present in the person’s egg or sperm cells and cannot be inherited by children. They guide treatment intensity; they say nothing about the family’s risk.

Should relatives be screened? Current mainstream guidance does not recommend routine testing of family members, because the absolute risk remains low and finding MGUS in a well person leads to lifelong monitoring without a proven way to prevent progression. Relatives can reasonably mention the family history to their own clinician so that an unexplained anemia or protein result is interpreted with that context in mind. A conversation with a genetic counselor is sensible where several first-degree relatives have had myeloma or related plasma cell disorders.

Who is most at risk of developing myeloma?

Age is the strongest factor by a wide margin. Mayo Clinic notes that risk rises steadily with age and that most people are diagnosed in their mid-60s; the NHS describes the disease as uncommon under 40. This tracks with the biology: plasma cells accumulate genetic damage over decades, and MGUS itself becomes more frequent in each successive decade of life.

Sex plays a smaller role. Men are somewhat more likely to develop myeloma than women, a difference observed consistently across populations, though the reason remains unclear.

Race is a significant and well-documented factor. The National Cancer Institute reports that myeloma is about twice as common in Black people as in white people in the United States, and it tends to be diagnosed at a younger age in Black patients. MGUS is also more prevalent in this group, suggesting the difference begins at the precursor stage. Researchers continue to investigate the inherited variations and environmental contributors behind this gap.

Other associations carry weaker or less certain evidence. Obesity has been linked to higher risk in observational studies. Some occupational exposures, including certain chemicals and radiation, have been associated with plasma cell disorders in specific settings, though the effect sizes are small and hard to disentangle from other factors. A personal history of MGUS is, of course, the clearest precursor of all.

Notably absent from the list are the lifestyle factors people most expect. Smoking, which drives many cancers, has not been convincingly tied to myeloma. Mayo Clinic is direct that there is no known way to prevent the disease. That is uncomfortable but also freeing: a myeloma diagnosis is not something a person brought upon themselves, and no amount of second-guessing past habits will change it.

How is multiple myeloma treated, and what should patients expect?

Treatment is decided by the hematology team, and the first decision is whether to treat at all. Smoldering myeloma is usually monitored with regular blood tests rather than treated, because starting therapy before organ damage appears has not been shown to help most people and carries its own burdens. Active myeloma, defined by the CRAB features or the laboratory markers described earlier, is treated.

Modern therapy combines several classes of medicine, typically in a course lasting several months before the team reassesses. The NIH National Cancer Institute’s patient summary groups the main approaches as follows: agents that block the proteasome, a cellular waste-disposal system plasma cells depend on heavily; agents that modulate the immune system and disrupt the marrow environment the clone relies on; monoclonal antibodies engineered to attach to surface proteins on plasma cells and mark them for destruction; and corticosteroids, which are directly toxic to malignant plasma cells. Newer immune therapies that redirect a patient’s own T cells against myeloma are used in specific circumstances.

For people fit enough, high-dose chemotherapy followed by an infusion of their own previously collected stem cells, an autologous transplant, remains a standard option. It aims to deepen the response achieved by initial treatment and is followed by a lower-intensity maintenance phase.

Supportive care runs alongside. Bone-strengthening medicines reduce fracture risk; infection prevention, adequate fluids, and prompt attention to kidney function protect against the complications that historically caused the most harm.

Myeloma is generally managed as a long-term, relapsing condition rather than one that is cured and forgotten. Response is measured by the M protein and light chain levels falling, and treatment is adjusted if they rise again. Choices among these options depend on age, fitness, kidney function, genetic features of the disease, and personal preference, all of which sit with the treating team and the patient together.

When should you see a doctor about possible myeloma symptoms?

Most back pain and most tiredness has nothing to do with myeloma, and this article is not an argument for panic every time a joint aches. It is an argument for pattern recognition. Book an appointment when symptoms persist beyond a few weeks, do not respond to the obvious fix, or arrive in combination.

Reasonable triggers for a routine visit include:

• Bone pain, especially in the back or ribs, that lasts more than a few weeks, disturbs sleep, or does not ease with rest.
• Tiredness or breathlessness on ordinary activity that is new and unexplained.
• Two or more significant infections in a year, particularly chest or urinary infections needing antibiotics.
• Unexplained weight loss, persistent thirst, or constipation alongside the above.
• A previous laboratory report mentioning high total protein, a monoclonal band, or MGUS that was never followed up.

Certain signs need same-day care rather than a routine slot. Seek urgent medical attention for sudden severe back pain with new numbness, weakness, or loss of bladder or bowel control, which can indicate spinal cord compression from a collapsed vertebra. The same applies to confusion, drowsiness, or vomiting with intense thirst, which can signal dangerously high calcium, and to a fever with shaking chills in someone already known to have a plasma cell disorder, since infections can escalate quickly when normal antibody production is suppressed. A fracture from a minor fall or no obvious injury also warrants prompt assessment.

When you attend, ask directly whether a full blood count, calcium, kidney function, and serum protein electrophoresis with free light chains would be appropriate. Naming the tests is not overstepping; it gives the clinician a clear place to start and saves the round of appointments that often precedes a myeloma diagnosis.

Frequently asked questions

What is the first sign of multiple myeloma?

Persistent bone pain, most often in the lower back or ribs, is the most commonly reported first symptom, according to Mayo Clinic and the NHS. Fatigue from anemia is the next most frequent. A significant number of people have no symptoms and are identified when a routine blood test shows high protein, low hemoglobin, raised calcium, or reduced kidney function that prompts further investigation.

Where does myeloma usually start?

Myeloma starts in the bone marrow, where a single plasma cell acquires genetic damage and begins multiplying. Because marrow is distributed through the skeleton, the disease typically involves many bones at once, particularly the spine, pelvis, ribs, and skull. Occasionally a solitary mass of plasma cells, a plasmacytoma, is found first, and clinicians monitor these closely because some progress to widespread disease.

How long can you go without knowing you have multiple myeloma?

Potentially years. Mayo Clinic notes that myeloma almost always begins as MGUS, a symptomless precursor that can persist for a long time, and a smoldering phase without organ damage can follow. Even active disease is often mistaken for ordinary back pain, tiredness, or infection for months. There is no fixed timeline, which is why persistent, unexplained symptoms deserve a blood test rather than continued waiting.

What are the early warning signs of myeloma?

The classic early features are summarized as CRAB: high calcium causing thirst and constipation, renal impairment usually silent on blood tests, anemia causing fatigue and breathlessness, and bone pain or fractures. Repeated infections and unexplained bruising are additional clues. Individually each is common and usually harmless; the combination, especially in someone over 60, is what should prompt testing.

What can be mistaken for multiple myeloma?

Myeloma is frequently confused with mechanical back pain, osteoporosis, iron-deficiency anemia, and kidney disease from diabetes or blood pressure. Conditions that mimic its laboratory picture include MGUS, Waldenström macroglobulinemia, light chain amyloidosis, and bone metastases from other cancers. Protein studies, imaging, and a bone marrow sample separate these, which is why a single abnormal result is never treated as a diagnosis.

What blood test detects multiple myeloma?

Serum protein electrophoresis is the central test. It separates blood proteins into bands and reveals a sharp spike when one plasma cell clone is producing a single abnormal antibody. Immunofixation identifies the antibody type, and a serum free light chain assay catches forms that electrophoresis alone can miss. A complete blood count, calcium, and kidney function tests are run alongside to show whether the protein is causing harm.

Is multiple myeloma hereditary?

Not in the usual sense. It is not caused by a single inherited gene, and most people diagnosed have no affected relatives. Having a parent or sibling with myeloma modestly increases risk, according to Mayo Clinic and the NHS, likely through many small inherited variations. Genetic changes found in a patient’s myeloma cells are acquired during life and cannot be passed to children.

Does MGUS always turn into myeloma?

No. Mayo Clinic reports that roughly 1% of people with MGUS progress to myeloma or a related condition each year, meaning most never do. MGUS requires no treatment, only periodic blood tests to confirm the protein level, hemoglobin, calcium, and kidney function remain stable. Having a baseline means any change is detected early, before bones or kidneys are damaged.

Who is most likely to get multiple myeloma?

Older adults, most of whom are diagnosed in their mid-60s according to Mayo Clinic. Men are somewhat more affected than women, and the National Cancer Institute reports the disease is about twice as common in Black people as in white people in the United States. A history of MGUS and a close relative with myeloma also raise risk. There is no proven way to prevent it.

When should I see a doctor about bone pain or tiredness?

See a clinician if bone pain lasts more than a few weeks, disturbs sleep, or comes with unexplained fatigue, repeated infections, or thirst. Seek urgent care for sudden severe back pain with numbness, weakness, or bladder changes, for confusion with intense thirst, or for fever with chills if you have a known plasma cell disorder. Asking for a blood count, calcium, kidney tests, and protein electrophoresis is reasonable.

References

• NHS – Multiple myeloma: Diagnosis
• MedlinePlus – Multiple Myeloma

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.